Chemical and immunological testing for faecel occult blood: a comparison of two tests in symptomatic patients. by Thomas, W. M. et al.
Br. J. Cancer (1992), 65, 618 620 © Macmillan Press Ltd.,
Chemical and immunological testing for faecel occult blood: a comparison
of two tests in symptomatic patients
W.M. Thomas, J.D. Hardcastle, J. Jackson & G. Pye
Department ofSurgery, University Hospital, Queen's Medical Centre, Nottingham NG7 2UH, UK.
Summary An established chemical faecal occult blood test (Haemoccult prepared without rehydration) has
been compared with a new immunological test (Hemeselect) in patients referred for investigation of lower
gastro-intestinal symptoms.
Hemeselect was shown to have a higher sensitivity for colorectal carcinoma (94.0% compared with 58.0%),
the greatest difference in sensitivity between the two tests being for rectal cancers.
Similarly Hemeselect was more sensitive than Haemoccult for colorectal adenomas (66.6% vs 33.3%), and
for inflammatory bowel disease (88.9% vs 33.3%).
However the enhanced sensitivity of Hemeselect for colorectal neoplasia and inflammatory bowel disease
was accompanied by a significant increase in the overall rate of positive reactions (32.8% of patients had a
positive Hemeselect reaction compared with 14.8% who had a positive Haemoccult test), and a reduction in
specificity (84.1% for Hemeselect vs 96.0% for Haemoccult).
Hemeselect is a more sensitive indicator of colorectal neoplasia in symptomatic subjects, trials of its use as a
screening test for asymptomatic neoplasia appear justified.
Faecal occult blood tests are potentially useful in the pre-
liminary assessment of subjects with symptoms of colorectal
disease (Leicester et al., 1983) and also for mass population
screening for asymptomatic colorectal neoplasia. The test
commonly used for screening, Haemoccult (Rohm Pharma)
has an estimated sensitivity in the range 50-65% for asymp-
tomatic cancers (Kewenter et al., 1988; Kronborg et al., 1989;
Hardcastle et al., 1989) and has been noted to be particularly
insensitive for rectal and caecal cancers, missing over 50% of
malignancies at these sites (Kronborg et al., 1989; Hardcastle
et al., 1989). In contrast over 70% of sigmoid cancers are
detected. One of the proposed mechanisms for this discrep-
ancy is that Haemoccult, which is essentially a test for the
Haematin moiety of Haemoglobin, relies on an optimum
degree of Haemoglobin degradation which is most commonly
achieved by blood loss from sigmoid cancers.
Immunological tests, not dependent on Haematin, should
reliably detect bleeding from rectal cancers, although they
may also be affected by excessive degradation of blood from
caecal cancers. Hemeselect (Smith-Kline Diagnostics) utilises
fixed chicken erythrocytes that have coated with an anti-
human haemoglobin antibody. Faecal matter is smeared onto
filter paper by the patients. Small discs of the paper are then
used to obtain a dilute faecal solution to which the coated
chicken erythrocytes are added, erythrocyte agglutination
occurs in the presence of haemoglobin in the faecal solution.
The aim of this study was to compare the sensitivity for
large bowel neoplasia of Haemoccult and Hemeselect in
patients with symptoms suggestive of large bowel neoplasia,
such information being imperative before further evaluation
of Hemeselect as a screening test is considered.
Methods
Three hundred and fifty patients with symptoms suggestive of
lower gastrointestinal neoplasia referred to two surgical out-
patient departments at the University Hospital, Nottingham
were asked to complete Haemoccult and Hemeselect tests on
each of three consecutive daily bowel motions, prior to the
out-patient appointment. Instructions were carefully formul-
ated so that both tests were completed with the same faecal
sample, thus minimising sampling error. They were asked to
omit foods, such as red meat and vegetables with high perox-
idase activity, known to interfere with the Haemoccult test
(Thomas et al., 1989) from their diet.
At the time of outpatient assessment patients underwent
routine clinical examination, including sigmoidoscopy, and
were referred for colonoscopy or flexible sigmoidoscopy and
double contrast barium enema.
The Haemoccult and Hemeselect tests were interpreted
independently in the Department of Surgery. Haemoccult
tests were read after the application of two drops of 1%
W.W. Hydrogen Peroxide, a blue discolouration at 30 s being
taken as a positive reaction. Rehydration of the test cards
prior to development was not performed. Hemeselect tests
were interpreted in accordance with the manufacturer's ins-
tructions, erythrocyte agglutination at a 1:8 dilution repre-
senting a positive reaction. Statistical comparisons have been
made using the Chi Squared test and Fischer's Exact Test.
Results
Of the 350 patients (median age 69 years, range 29-86 years;
211 males and 139 females) studied, 332 (94.8%) satisfac-
torily completed both tests, of these 49 (14.8%) had a
positive Haemoccult test and 109 (32.8%) a positive Heme-
select test (X2 = 29.43, d.f. = 1, P<0.001).
Following further investigation 50 patients were shown to
have a colorectal carcinoma; of these 29 (58.0%) had a
positive Haemoccult test and 47 (94.0%) a positive Heme-
select test, (X2 =17.76, d.f. = 1, P<0.001).
The site dependent sensitivity is shown in Table I, Heme-
select being more sensitive for carcinoma at all sites within
the colorectum; although the difference in sensitivity was
particularly evident for rectal cancers where Hemeselect
detected 46.0% more of the cancers than Haemoccult, for
Sigmoid/Descending colon cancers the difference was 20.0%,
and for right sided cancers, 33.3%.
The sensitivity of both tests was independent of tumour
stage (Table II).
A total of 26 adenomatous polyps were diagnosed in 21
patients (Table III). Seven (33.3%) patients had a positive
Haemoccult test compared with 14 (66.6%) who had a
positive Hemeselect test (X2 = 4.65, d.f. = 1, P = 0.03).
Nine patients were shown to have an inflammatory condi-
tion affecting the colon or rectum (Table IV), of these three
(33.39%) had a positive Haemoccult test and eight (88.9%) a
positive Hemeselect test (Fisher's test, P = 0.02).
The specificity for neoplasia or inflammatory bowel has
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Table I Sensitivity for carcinoma - tumour site
Positive Sensitivity
Total Haemoccult Hemeselect difference
Rectum 25 13 (52.0%) 24 (96.0%) 46.0%
Sigmoid/Descending 15 11 (73.3%) 14 (93.3%) 20.0%
colon
Transverse colon 1 0 1
Ascending colon/ 9 5 (55.5%) 8 (88.8%) 33.3%
caecum
Total 50 29 (58.0%) 47 (94.0%)
Table II Sensitivity for carcinoma - tumour stage
Positive
Duke's stage Total Haemoccult Hemeselect
A 8 4 (50.5%) 7 (87.5%)
B 21 11 (52.3%) 21 (100%)
C 13 9 (69.2%) 12 (92.3%)
Distance metastases 8 5 (62.5%) 7 (87.5%)
Total 50 29 (58.0%) 47 (94.0%)
Table III Sensitivity for adenoma
Positive
Size oflargest polyp Number Haemoccult Hemeselect
<1.0cm 0
1.0- 1.9 cm 10 3 (30%) 6 (60%)
>2.0cm 11 4 (36%) 8 (73%)
Total patients 21 7 (33%) 14 (66%)
Table IV Inflammatory bowel disease
Positive
Patients Haemoccult Hemeselect
Ulcerative colitis 3 2 3
Crohn's disease 1 0 0
Radiation colitis 1 0 1
Non-specific proctitis 4 1 4
Total 9 3 (33%) 8 (88.9%)
been calculated according to usual definition, i.e. the propor-
tion of people with negative tests who were shown to be free
of the disease in question. Of the 252 patients who were
disease-free (did not have colonic neoplasia or inflammatory
bowel disease) 242 had negative Haemoccult tests, a speci-
ficity of96.0%. In comparison 212 were Hemeselect-negative,
a specificity of 84.1% (x2 = 19.98, d.f. = 1, P<0.0001).
Discussion
Faecal occult blood testing of patients with symptoms of
colorectal disease remains a controversial, but widespread
practice. We believe that patients with such symptoms should
undergo appropriate endoscopic or radiological investigation,
however other authors have emphasised the usefulness of
preliminary faecal occult blood testing, especially in identify-
ing subjects worthy of urgent investigation (Leicester et al.,
1983).
In this respect Haemoccult, interpreted without rehydra-
tion, would appear to be of limited value, detecting only 58%
of symptomatic cancers. Previous series have reported a sen-
sitivity of 45-81% for symptomatic cancers (Barrison et al.,
1985; Aldercreutz et al., 1984); an earlier report from this
department demonstrated a sensitivity of 72% when Haem-
occult was performed over 3 days (Farrands & Hardcastle,
1983), the lower overall sensitivity seen in the present study
may reflect the large number of rectal tumours in the cohort
ofpatients with carcinoma. One method ofimproving Haem-
occult sensitivity which has been explored is the rehydration
of the test cards before the application ofhydrogen peroxide,
however this also significantly reduces specificity for neo-
plasia (Mandel et al., 1989; Kewenter et al., 1988) and in the
present study all Haemoccult tests were interpreted without
rehydration.
The excellent sensitivity of Hemeselect makes this a more
suitable test for use in symptomatic subjects, our results
suggest that approximately a third ofpatients with symptoms
compatible with colorectal neoplasia could be given priority
outpatient assessment and investigation and that 98% of
those with a malignancy would be identified by the F.O.B.
test. St John et al. (1990) have described a similar sensitivity
(95%) for symptomatic cancers, although in their series 89%
of patients also had a positive Haemoccult test.
It seems probable that the main reason for the enhanced
sensitivity of Hemeselect for neoplasia is its ability to detect
small quantities of faecal blood (Yoshida et al., 1986), how-
ever it appears that lack of haemoglobin degradation may
also adversely affect the performance of Haemoccult as the
greatest difference in sensitivity between the tests was for
rectal cancers.
The potential use of Hemeselect as a highly sensitive
screening test for asymptomatic neoplasia is also raised by
this study. Our results suggest that it would also be more
sensitive than Haemoccult for asymptomatic neoplasia, but
that this improvement would be achieved at the expense of
specificity. The specificity of 84.1% for colorectal neoplasia
achieved in the present study would be inadequate for a
screening test although an improvement in specificity would
be expected if the tests were used in asymptomatic individ-
uals where blood loss from benign conditions would have less
influence. In accordance with the United Kingdom Coordin-
ating Committee for Cancer Research (UKCCCR) recom-
mendations regarding the evaluation of F.O.B. tests a
preliminary study to assess the overall positivity rate in
asymptomatic subjects is now being undertaken and will be
followed by a larger screening study to determine the com-
parative yield of neoplasia and specificity of Haemoccult and
Hemeselect in asymptomatic subjects.
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